SAN FRANCISCO--(BUSINESS WIRE)--Osteologix Inc. (OTCBB:OLGX) today announced that Philip J. Young, President and CEO of Osteologix, will give a presentation entitled, “Pricing Considerations When Launching a Drug” to over 300 executive delegates at the Eye for Pharma Early Commercialization, Lifecycle and Portfolio Management Congress 2007 on October 25th at the Barcelo Sants Hotel in Barcelona, Spain. The presentation will address the complex issues of drug pricing once a company reaches the Launch stage of commercialization. Young brings to the table over twenty-five years of broad experience with biopharmaceutical development and commercialization. He has been the driving force behind numerous successful drug launches; including Nutropin® (Somatropin [rDNA origin] for injection) and Genotropin®(Somatropin [rDNA origin] for injection), for pediatric growth hormone deficiency, and Corlopam® (Fenoldopam Mesylate Injection, USP) for acute hypertensive episodes.. With a proven track record of success, Mr. Young is leading the development of Osteologix’s principal compound, NB S101, which is currently in Phase II clinical development for the treatment and prevention of osteoporosis. The company is set to release Phase II data in the fourth quarter of 2007.
